Brian Conway

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi request reprint Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Canada
    Int J Drug Policy 18:437-43. 2007
  2. pmc Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
    Harout K Tossonian
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada
    Open Virol J 1:8-13. 2007
  3. ncbi request reprint Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine
    B Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z 1Y8, Canada
    Clin Infect Dis 30:S130-4. 2000
  4. ncbi request reprint Directly observed therapy for the management of HIV-infected patients in a methadone program
    Brian Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z2C7, Canada
    Clin Infect Dis 38:S402-8. 2004
  5. ncbi request reprint The role of adherence to antiretroviral therapy in the management of HIV infection
    Brian Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Faculty of Medicine, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 45:S14-8. 2007
  6. ncbi request reprint A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective
    Brian Conway
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Infect Dis 41:S73-8. 2005
  7. ncbi request reprint Pharmacology and clinical experience with amprenavir
    B Conway
    University of British Columbia, Viridae Clinical Sciences, 1134 Burrard Street, Vancouver BC, V6Z 1Y8, Canada
    Expert Opin Investig Drugs 9:371-82. 2000
  8. ncbi request reprint Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program
    Harout K Tossonian
    Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 45:324-7. 2007
  9. doi request reprint Primary drug resistance in antiretroviral-naïve injection drug users
    Harout K Tossonian
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada
    Int J Infect Dis 13:577-83. 2009
  10. pmc Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    Can J Gastroenterol 21:447-51. 2007

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Canada
    Int J Drug Policy 18:437-43. 2007
    ..Moreover, the treatment of HCV in current and former IDUs within a multidisciplinary DOT program can be successfully undertaken, resulting in ETRs similar to those reported in randomized controlled trials...
  2. pmc Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
    Harout K Tossonian
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada
    Open Virol J 1:8-13. 2007
    ..033). Mutations at codon 135 do not affect response rates, but affect the pattern of development of NNRTI resistance mutations. This has important implications for the subsequent use of newer NNRTIs such as etravirine in salvage therapy...
  3. ncbi request reprint Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine
    B Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z 1Y8, Canada
    Clin Infect Dis 30:S130-4. 2000
    ....
  4. ncbi request reprint Directly observed therapy for the management of HIV-infected patients in a methadone program
    Brian Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, V6Z2C7, Canada
    Clin Infect Dis 38:S402-8. 2004
    ..Treatment-limiting hepatic toxicity was rare. A DOT program of coadministered methadone and HAART can be implemented with good results, even for patients who continue to use cocaine...
  5. ncbi request reprint The role of adherence to antiretroviral therapy in the management of HIV infection
    Brian Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Faculty of Medicine, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 45:S14-8. 2007
    ....
  6. ncbi request reprint A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective
    Brian Conway
    Department of Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Clin Infect Dis 41:S73-8. 2005
    ..Our ultimate goal is to ensure that, even in treating IDUs in the inner city, no patient is left behind...
  7. ncbi request reprint Pharmacology and clinical experience with amprenavir
    B Conway
    University of British Columbia, Viridae Clinical Sciences, 1134 Burrard Street, Vancouver BC, V6Z 1Y8, Canada
    Expert Opin Investig Drugs 9:371-82. 2000
    ..Its specific role in therapy can only be clarified once the results of ongoing trials (particularly comparative trials of its use in previously treated patients) are available...
  8. ncbi request reprint Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program
    Harout K Tossonian
    Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 45:324-7. 2007
    ....
  9. doi request reprint Primary drug resistance in antiretroviral-naïve injection drug users
    Harout K Tossonian
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada
    Int J Infect Dis 13:577-83. 2009
    ..We evaluated the prevalence of primary HIV drug resistance in a population of 128 injection drug users (48 female) prior to initiating antiretroviral therapy...
  10. pmc Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    Can J Gastroenterol 21:447-51. 2007
    ..Spontaneous clearance of hepatitis C virus (HCV) occurs in approximately 25% of individuals...
  11. ncbi request reprint The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program
    Jesse D Raffa
    Department of Statistics, University of British Columbia, Vancouver, BC, Canada
    Drug Alcohol Depend 89:306-9. 2007
    ..We sought to evaluate the impact of ongoing illicit drug use on methadone adherence within a DOT program for the treatment of HIV-infection...
  12. ncbi request reprint Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada
    J Gastroenterol Hepatol 22:1519-25. 2007
    ....
  13. doi request reprint Current approaches to HCV infection in current and former injection drug users
    Jason Grebely
    Vancouver Coastal Health, Vancouver, British Columbia, Canada
    J Addict Dis 27:25-35. 2008
    ..The development of such programs may be quite complex, but the ultimate benefit (for the treated population and for society as a whole) is certainly worth the effort...
  14. ncbi request reprint Barriers associated with the treatment of hepatitis C virus infection among illicit drug users
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
    Drug Alcohol Depend 93:141-7. 2008
    ..Illicit drug users account for the majority of cases of HCV infection in the developed world, but few have received treatment...
  15. ncbi request reprint Hepatitis C virus reinfection in injection drug users
    Jason Grebely
    Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada
    Hepatology 44:1139-45. 2006
    ..23; 95% CI, 0.10-0.51, P < .001). In conclusion, individuals with clearance of HCV infection may have a lower risk of acquiring HCV than individuals who have never been infected, despite ongoing exposure to HCV...
  16. ncbi request reprint Conference report - antiretroviral therapy update from the 9th European AIDS Conference
    Brian Conway
    Department of Pharmacology Therapeutics, University of British Columbia, Vancouver, British Columbia
    MedGenMed 5:30. 2003
  17. ncbi request reprint Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver?
    Brian Conway
    Department of Anesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine, University of British Columbia, 201 1200 Burrard Street, Vancouver, BC, V6Z2C7, Canada
    Curr Infect Dis Rep 13:68-74. 2011
    ..As we redefine the potential benefits of cART on a broader scale, let us not sacrifice the gains that have been made until we are more certain of the potential benefits of the "seek and treat" strategy...
  18. ncbi request reprint Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
    Martin S Hirsch
    Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 37:113-28. 2003
    ..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation...
  19. ncbi request reprint Drug resistance mutations in HIV-1
    RICHARD T D'AQUILA
    Vanderbilt University Medical Center, Nashville, TN, USA
    Top HIV Med 11:92-6. 2003
  20. doi request reprint CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy
    Marina B Klein
    Department of Medicine, Divisions of Infectious Diseases Immunodeficiency, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    Contemp Clin Trials 29:617-30. 2008
    ..Effective prevention of a broad range of neuropsychiatric symptoms by citalopram has the potential to diminish PEG-IFN-alpha associated morbidity and consequently, allow a greater number of patients to complete full therapy...
  21. ncbi request reprint Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations
    Jesse D Raffa
    J Acquir Immune Defic Syndr 47:397-9. 2008
  22. ncbi request reprint Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy
    Stephen D Shafran
    University of Alberta, Edmonton, Alberta, Canada
    Ann Intern Med 137:734-7. 2002
    ..S. Public Health Service/Infectious Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART...
  23. ncbi request reprint A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164)
    Sharon L Walmsley
    Department of Medicine, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 45:418-25. 2007
    ..The primary endpoint was the percentage of patients with a 3-month sustained HIV RNA level <50 copies/mL...
  24. ncbi request reprint Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz
    Frank van Leth
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Antivir Ther 9:721-8. 2004
    ..To assess whether differences in safety profiles between nevirapine (NVP) and efavirenz (EFV), as observed in the 2NN study, translated into differences in 'health related quality of life' (HRQoL)...
  25. ncbi request reprint A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 40:140-8. 2004
    ..The pharmacokinetic profile of clevudine was proportional to the dose. In conclusion, these results demonstrate the tolerability and potent activity of clevudine in HBV-infected patients and support further clinical study...
  26. ncbi request reprint A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection
    Frederick M Hecht
    University of California San Francisco, San Francisco, CA 94110, USA
    J Infect Dis 194:725-33. 2006
    ....
  27. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  28. ncbi request reprint And now for something completely simple
    Brian Conway
    Expert Rev Anti Infect Ther 2:1-4. 2004
  29. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  30. ncbi request reprint Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study)
    Andrew R Zolopa
    Stanford University School of Medicine, Stanford, CA 94305 5107, USA
    Clin Infect Dis 41:92-9. 2005
    ..We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes...
  31. ncbi request reprint Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
    ..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
  32. ncbi request reprint Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies
    Stephen D Shafran
    Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2B7
    Clin Infect Dis 34:658-61. 2002
    ..96%, and its overall accuracy was 99.96%. The Merlin POC test is highly accurate for the detection of HIV antibodies...
  33. pmc Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 76:1753-61. 2002
    ..These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence...
  34. ncbi request reprint Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen
    Mona R Loutfy
    Department of Medicine, University of Toronto, Toronto, Canada
    HIV Clin Trials 8:259-68. 2007
    ....
  35. ncbi request reprint Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel
    Martin S Hirsch
    Top HIV Med 11:150-4. 2003
    ..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing...
  36. ncbi request reprint Drug resistance mutations in HIV-1
    Victoria A Johnson
    Veterans Affairs Medical Center, and University of Alabama School of Medicine, Birmingham, AL, USA
    Top HIV Med 11:215-21. 2003
    ..Drugs that have been approved by the US Food and Drug Administration (FDA) or available through expanded access protocols are included...
  37. pmc Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection
    Andrew J Leigh Brown
    University of Edinburgh, Edinburgh, Scotland
    J Virol 78:2242-6. 2004
    ..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection...
  38. ncbi request reprint Update of the drug resistance mutations in HIV-1: Fall 2005
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 13:125-31. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility...
  39. ncbi request reprint Morphologic changes in HIV-infected men: sorting fact from fiction
    Milan Khara
    J Acquir Immune Defic Syndr 40:119-20. 2005
  40. ncbi request reprint Update of the Drug Resistance Mutations in HIV-1: 2005
    Victoria A Johnson
    Veterans Affairs Medial Center, Birmingham, AL, USA
    Top HIV Med 13:51-7. 2005
    ..A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that, in isolation, may not reflect prior drug selective pressure or reduced drug susceptibility...
  41. ncbi request reprint Monoclonal antibody hNM01 in HIV-infected patients: a phase I study
    Bruce J Dezube
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Clin Virol 31:S45-7. 2004
    ..hNM01 is a humanized monoclonal antibody that binds to the V(3) region of the HIV-1 envelope protein gp120. This binding leads to the activation of complement and the disruption of the viral envelope...
  42. ncbi request reprint Update of the drug resistance mutations in HIV-1: 2004
    Victoria A Johnson
    Veterans Affairs Medical Center, Birmingham, AL, USA
    Top HIV Med 12:119-24. 2004